5 Biotech Stocks to Buy Today According to Ken Fisher

3. GlaxoSmithKline plc (NYSE:GSK)

Fisher Asset Management’s Stake Value: $803 million

Percentage of Fisher Asset Management’s 13F Portfolio: 0.44%

Number of Hedge Fund Holders: 36

GlaxoSmithKline plc (NYSE:GSK) is a pharmaceutical product, vaccine, and other healthcare products developer and manufacturer that is based out of Brentford, United Kingdom. It is also more than three centuries old since it was set up in 1715. The company has biotechnology manufacturing plants and has acquired several biotech firms as well.

Fisher Investments held an $803 million stake in GlaxoSmithKline plc (NYSE:GSK) during Q4 2021, by owning 18 million shares making it the company’s largest investor according to Insider Monkey’s research. Insider Monkey’s fourth quarter 2021 survey of 924 hedge funds revealed that 36 had invested in the firm.

GlaxoSmithKline plc (NYSE:GSK) posted £9.5 billion in revenue and a GAAP EPS of £0.15 by the end of its fiscal fourth quarter. At the same time, the company outlined that it expects its sales to grow between 5% and 7% during the calendar year 2022.

GlaxoSmithKline plc (NYSE:GSK)’s second largest investor is Jim Simons’ Renaissance Technologies which owns 10 million shares worth $450 million.